GHRP-6
Also called SKF-110679
What to know about GHRP-6
GHRP-6 is a growth-hormone secretagogue and ghrelin-receptor agonist studied mainly through acute endocrine challenge experiments.
- How it may work
- It activates the ghrelin receptor, stimulating growth-hormone release and often appetite-related signalling; hypothalamic and pituitary pathways both contribute.
- What research found
- Small human studies report acute growth-hormone responses and explored how native GHRH modifies the effect. They do not establish long-term body-composition outcomes.
- What is not settled
- Human long-term safety is not established. Potential concerns include altered glucose control, appetite, fluid balance, and broader pituitary-hormone effects.
- Research and product status
- GHRP-6 has no licensed U.S. product and is prohibited in sport under WADA's growth-hormone secretagogue category.
Research reference
- Research amount range
- 100–200 mcg per administration — not a starting amount
- Reference frequency
- Twice a day — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Model accumulation timescale
- ~2 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Small human studies measured acute growth-hormone release and food intake over hours. They do not establish when muscle, recovery, sleep, or body-composition outcomes appear.
- When to assess
- No strong long-duration human outcome study provides a week at which commonly claimed goals should be judged. Acute hunger or a hormone rise is not a durable outcome.
- Conditions and limitations
- The experiments do not validate bedtime use, fasting, exercise timing, or pairing with a GHRH analogue as necessary for a meaningful longer-term result.
- When to stop
- No validated target, course length, maintenance phase, or quit rule exists for common research use. Do not increase or prolong exposure solely because a claimed result is absent.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C46H56N12O6
- Mol. weight
- 873 Da
- CAS
- 87616-84-0
- PubChem CID
- 4345065
External references
Vial arithmetic
Published research contexts for GHRP-6 describe 100–200 mcg per administration. Descriptive only, not a recommendation.
Roughly 15–20 minutes in plasma.
An early growth-hormone-releasing hexapeptide given to human volunteers, but no trial fixes a subcutaneous amount or schedule; the circulating figures are community-derived, so no schedule table is shown.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 2hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GHRP-6 (SKF-110679) secretagogue literatureOne of the first growth-hormone-releasing peptides taken into human study; injected amounts in circulation are community-derived, not trial-established.